ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Stock Price Down 1.9% – Here’s Why

Shares of ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) fell 1.9% during trading on Monday . The stock traded as low as $32.84 and last traded at $33.08. 17,314 shares traded hands during trading, an increase of 59% from the average session volume of 10,871 shares. The stock had previously closed at $33.72.

ALPS Medical Breakthroughs ETF Stock Down 0.2 %

The stock has a 50 day moving average price of $37.53 and a two-hundred day moving average price of $36.78.

Institutional Trading of ALPS Medical Breakthroughs ETF

Hedge funds have recently modified their holdings of the stock. International Assets Investment Management LLC bought a new position in shares of ALPS Medical Breakthroughs ETF in the 3rd quarter valued at about $61,430,000. Jane Street Group LLC bought a new position in ALPS Medical Breakthroughs ETF in the third quarter valued at approximately $366,000. Finally, Griffin Asset Management Inc. grew its holdings in ALPS Medical Breakthroughs ETF by 31.2% during the 3rd quarter. Griffin Asset Management Inc. now owns 30,135 shares of the company’s stock worth $1,125,000 after acquiring an additional 7,170 shares during the period.

ALPS Medical Breakthroughs ETF Company Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.